Track topics on Twitter Track topics that are important to you
Japan's Takeda Pharmaceutical Co. Ltd. (TKPYY.PK) announced Thursday that new phase 3 data show investigational subcutaneous or SC formulation of Vedolizumab meets primary endpoint in achieving clinical remission at week 52 in patients with moderately to severely active ulcerative colitis.
Original Article: Takeda Pharma: VISIBLE 1 Study Of Vedolizumab Meets Primary EndpointNEXT ARTICLE
The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...